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Abstract
Background: Hybridization probe melting analysis can be complicated by the 
presence of sequence variation (non-pathogenic polymorphisms or other 
mutations) near the targeted mutation. We investigated the use of ‘masking’ 
probes to differentiate alleles with similar probe melting temperatures.
Materials and Methods: Selected sequence variation was masked by 
incorporating deletions, unmatched (non-complementary) nucleotides, or 
universal bases into hybridization probes. Such masking probes create a 
probe:target mismatch with all possible alleles at the selected polymorphic 
location. Any allele with additional variation at another site is identified by a 
lower probe melting temperature than alleles that vary only at the masked 
position. This technique was applied to RET proto-oncogene and HPA6 
mutation detection using unlabeled hybridization probes, a saturating 
dsDNA dye, and high-resolution melting analysis.
Results: Masking probes clearly distinguished all targeted mutations from 
polymorphisms when at least one base pair separated the mutation from the 
masked variation. Polymorphisms immediately adjacent to mutations could 
usually be masked, except in certain cases, such as with single base 
deletion probes when both adjacent positions have the same polymorphic 
nucleotides. The masking probes can also localize mutations to specific 
codons or nucleotide positions.
Conclusion: Masking probes can be a useful tool to simplify hybridization 




Closed-tube method that can target and genotype 
specific mutations within larger amplicon
- similar to Hybprobe technique except probes are unlabeled
Protocol
1. Asymmetric PCR - to increase single-stranded product
Probe is 3’ phosphorylated 
to eliminate extension
2. Hybridize with unlabeled probe 
followed by high resolution melting analysis
Probe-target duplex
Detection by dsDNA binding dye: LCgreen PLUS
Table 1: Sequence Variation 
















































































13 768 2304 E768D GAG >GAC769 2307 L769L CTT >CTGc
a Nucleotide position of sequence variation using RET 
cDNA sequence derived from RET  mRNA GenBank 
NM_020630, where nucleotide position 181 is +1 (‘A’ of the 
ATG start codon).
b  Sequence variation is heterozygous unless otherwise 
stated in the text. Wildtype codon sequence is listed > 
nucleotide of change is in bold. 
c Polymorphism.
Samples:
- De-identified genomic DNA samples were 
received from the Mayo Clinic (Table1).
- All variant samples have been genotyped 
as heterozygous unless otherwise stated.
Asymmetric PCR with unlabeled probes:
- Approximately 50 ng of DNA sample and 
0.5 uM of unlabeled probe were added to a 
10 uL PCR reaction using Roche LightCycler
FastStart DNA Master Hybridization Probe kit and LCGreen™ Plus dye (Idaho 
Technology). Generally, the primers were used at 0.55 uM with a 1:10 ratio (Table 2).
- PCR on the Lightcycler®
- 10 min UNG step at 50°C and 10 min PCR activation at 95°C.
- 60 cycles of PCR: denaturation for 1 sec at 95°C, annealing for 1 sec at 62°C 
and elongation for 10 sec at 72°C.
- Duplexing procedure: After amplicon melt protocol ended at 95°C, samples were 
cooled to 40°C in the LightCycler, then placed at 4°C for >10 minutes.
High-resolution melting analysis for unlabeled probes:
Acquire temp 55 or 60°C, final temp 95°C. Raw data was converted to derivative plots.
Table 2: Primers and Probes
RET
exon Primersa
Amplicon Codon of 







WT 609/611 (30bp) 
WT 618/620 (31bp)
g g c ta tg g c a c cTGC aa c TGC ttc c c tg a g




WT exon 11 (27bp) 
WT 634 (31bp)
c g t g c g G C A c a g c t c Gt c G C A c a g tg g  
tg c g a tc a c c g tg c g G C A c a g c t c Gt c G CA c
13 ACTTGGGCAAGGCGATGCAG
GAACAGGGCTGTATGGAGC
274 768,769 WT exon 13 (30bp) CCCGAGTGAGCTICGAGACCTGCTGTCAGA
HPA6 TGGGATCCCAGTGTGAGTGCTCA
AGAAGTCGTCACACTCGCAGTAC
180 489 WT HPA6 (31bp) 
MUT-specific (31bp)
CTGCAGACGGGCTGACCCTCICGGGGGCTGC
c t g c a g a c g g g c t g a c c c t c CT g g g g g c t g c
a Primers are listed 5' to 3', with the forward primer above the reverse primer.
b The underlined codons contain a polymorphism, while the other codons contain pathogenic mutations. The HPA6 mutation and polymorphism is in the 
same codon, 489. 
c WT - wild type. MUT- mutation.
d Probe sequences are wild type and listed 5' to 3'. RET  exon 10 and 13 are forward probes, while RET  exon 11 and HPA6 are reverse probes. The 
possible mutation locations are highlighted in bold and the polymorphism locations are underlined. The masking probes have the same sequence as 
the wild type probes, except at the incorporated masking mismatch(es) displayed in each figure. The universal base and unmatched nucleotide masking 
probes were the same size (base pair) as the wild type probes, while the masking deletion probes were reduced in size by the number of deleted 
nucleotides from the wild type probe sequence.
WT probe
ssDNA V  V V  V
WT allele 
match
variant allele mutant allele 
1 mismatch
X X
mutant + variant allele 
2 mismatches
If similar Tm with wild type probe: 
Benign polymorphism - false positive 
Multiple mutations - miscall mutation
Masking Technique:
Masking selected sequence variation by incorporating 
mismatches into melting analysis probes
Deletions
unmatched (non-complementary) nucleotides 
universal bases (5’ Nitroindole)
Masking
probe A A
ssDNA Y  V  YX
WT allele masked variant allele 
1 mismatch
X X X
















- RET exon 13 has a common benign 
polymorphism (non-coding strand A>C) 
near a pathogenic mutation (Fig 1A).
- Both the polymorphism and the targeted 
mutation have one mismatch with the wild 
type probe, which resulted in similar probe 
melting temperatures (Fig 1B).
- Masking probes with a universal base, deletion, or an unmatched nucleotide at 
the non-targeted polymorphism location were evaluated (Fig 1C-F).
* Unmatched nucleotides used for the masking probes did not complement the 
possible nucleotides at the polymorphism location (non-coding strand: A or C).
- Each masking probe reduced all possible alleles to one mismatch status with the 
probe, creating a nearly identical Tm for the masked polymorphism allele as for the 
wild type allele.
- The targeted mutant allele had an additional mismatch with the masking probes 
and was clearly distinguished by a 4°C lower Tm than the wild type or masked 
polymorphism alleles.
Legend: A: The diagram illustrates RET exon 13 with the pathogenic codon 768 in red and the 
polymorphism codon 769 in blue, while ‘X’ represents the variant position within the codons. The masking 
probes have wild type sequence with an incorporated mismatch of a universal base, unmatched 
nucleotide or deletion at the polymorphism location, represented by the ‘V’. The graphs (B-F) are 
derivative plots of unlabeled probe high-resolution melting analysis data. For each graph: the black curve 
is homozygous wild type, the red curve is the heterozygous mutation at codon 768(GAG>GAC), the dark 
blue curve is heterozygous for the codon 769 polymorphism and the light blue curve is homozygous for 
the codon 769 polymorphism. Two melting temperature ranges are underlined on each panel, listing 
which alleles melted at each Tm range. B: The wild type probe (WT exon 13 probe). The codon 769 
polymorphism was masked by four different masking probes: C: deletion probe, D: universal base probe 
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- RET exon 11 has two codons 
of possible pathogenic mutations 
at 630 and 634, and a polymorphism 
at codon 631 (Fig 2A).
- In order to analyze the two 
pathogenic codons but not the 
polymorphism, a masking deletion 
and two unmatched nucleotide 
probes were tested.
- With all three probes, the codon 631 polymorphism was masked from 
analysis with a nearly identical Tm as the wild type allele, allowing the lower 
Tm mutant alleles to be clearly detected (Fig 2C-E).
Legend: A: The diagram illustrates RET exon 11 with pathogenic codons 630 and 634 
shown in red, with the codon 631 polymorphism is blue (‘X’ for codon position). The masking 
probes have wild type sequence that incorporates either a deletion or an unmatched 
nucleotide at the polymorphism location, represented by the ‘V’. The graphs (B-E) are 
derivative plots of unlabeled probe high-resolution melting analysis data. For each graph: 
the black curve is homozygous wild type, the red curves are three unique heterozygous 
mutations within codon 634 (TGC>CGC, GGC, and TCC), while the blue curve is 
heterozygous for the codon 631(GAC>GAT) polymorphism. B: The wild type probe (WT 
exon 11 probe), over codons 630, 631 and 634. The codon 631 polymorphism was masked 
by three different masking probes: C: deletion probe, D: unmatched nucleotide ‘T’ or E: 
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Locating the Position of Sequence Variation Under Probes
Figure 3
Results:
- RET exon 10 mutations are mainly restricted to four 
pathogenic codon locations: 609, 611, 618, and 620.
- Although the wild type probes can detect sequence 
variation, they cannot identify which codon contains the 
mutation (or even if the detected sequence variation is 
within a pathogenic codon) due to similar Tms (Fig 3B, E)
- To locate the mutation to a particular pathogenic codon, 
masking probes had a three base pair deletion over one 
codon (Fig 3A).
- In each case, mutations within the masked codon were 
as stable as the wild type allele, whereas alleles with the 
mutation outside of the masked codon had an additional 
mismatch with the probe and were clearly identified by 
lower Tms (Fig 3C and D, F and G).
Legend: A: The diagram illustrates RET exon 10 where pathogenic 
mutations can be any nucleotide change within codons 609, 611, 618 
and 620; all of wild type nucleotide sequence TGC. Each masking 
probe has a three base pair deletion of the wild type probe sequence 
over one pathogenic codon as illustrated. The codons predicted to be 
masked by each probe are listed by codon color (BLUE or RED) 
under ‘masked mutant codons’. For the graphs (B-G): heterozygous 
mutations at codons 609 and 618 are the blue traces, heterozygous 
mutations at codons 611 and 620 are the red traces and the black 
traces are homozygous wild type samples. Codons 609/611 data are 
displayed in the left panels and codons 618/620 data are displayed in 
the right panels. Two melting temperature ranges are underlined for 
each graph with codon mutant alleles (MUT), wild type alleles (WT) 
and masked codon mutant alleles (MASK) noted in each panel. B: 
The wild type probe (WT 609/611 probe) over the codons 609 and 
611. C: Masking 609 deletion probe. D: Masking 611 deletion probe. 
E: The wild type probe (WT 618/620 probe), over the codons 618 and 
620. F: Masking 618 deletion probe. G: Masking 620 deletion probe. 
The five unique mutations at codons 609/611 and ten unique 















B. WT 609/611 probe
Exon 10 618 620




71 74 77 80







611 MUT WT &
609 MASK












69 72 75 78
F. 618 deletion probe
620 MUT WT &
618 MASK
G. 620 deletion probe
62
618 MUT WT &
620 MASK
i i i i i r ~
65 68 71 
Temperature (°C)
Masking Sequence Variation Immediately 
Adjacent to the Targeted Mutation
Figure 4
Results:
- The positional effects of single base masking deletions in the 
probe relative to targeted mutations are shown in Figure 4.
- Five different single base deletion probes were designed 
across RET exon 11 codon 634 (Fig. 4A)
- Alleles with mutations in the second position of codon 634 
(blue) had Tms 3-4°C below the wild type allele with all probes, 
except when the probe deletion was over the mutation site 
masking all three mutations (Probe 4, Fig. 4 F).
- Similarly, a mutation at the third position of codon 634 (light 
blue, (TGC>TGG)) had a Tm 2-3°C below the wild type allele 
with all probes, except when the deletion was over the 
mutation site, masking only this mutation (Fig. 4G).
- Mutations at the first position of codon 634 (red) were also 
masked by probes with a deletion over the mutation site (Fig. 
4E). However, when the deleted base position was 
immediately adjacent to these mutations (Fig. 4D and 4F), the 
Tms of the mutations were very similar (within 0.8°C) to the 
wild type Tm.
* Using an unmatched ‘T’ or ‘G’ nucleotide for masking 
instead of the deletion allowed clear distinction between the mutant 
and wild type alleles (data not shown).
Legend: A: The diagram illustrates RET exon 11 codon 634 (boxed) of the 
wild type sequence TGC. Each masking probe has a one base pair deletion 
of the wild type sequence, near or within codon 634 as illustrated in the 
diagram. The mutations listed at the three nucleotide positions of codon 634 
and their melting curve traces are color coded. The three unique 
heterozygous mutations at the first position of codon 634 are red, the three 
unique heterozygous mutations at the second position of codon 634 are blue, 
while the heterozygous mutation at the third position of codon 634 are light 
blue. The black melting curve traces are homozygous wild type samples. B: 
Wild type probe (WT 634 probe). C-G: Masking deletion probes 1 through 5. 
Mutations that should be masked by a deletion probe are noted in the panels 
by the word ‘Mask’ in the mutation color (red, dark blue or light blue). The 
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- The HPA6 c.1544G>A mutation is immediately adjacent to the 
polymorphism c.1545G>A or C.
- Use of the masking deletion probes increased the Tm separation between 
wild type (GG, GA, GC) and mutant alleles (AG, AA, AC), with an exception 
(Fig. 5).
- The wild type ‘GA’ and the mutant ‘AG’ allelic nucleotide sequences resulted 
in very similar Tms (Fig. 5B and E). Both these alleles are predicted to have 
only a single nucleotide bulge with the masking deletion probe (Fig. 5C).
* Single base deletion probes create a single base bulge in the target DNA 
strand, usually at the position opposite the deleted base, but the bulge can be at 
alternate positions depending on the nearest neighbors. An immediately adjacent 
mutation would be expected to result in further destabilization (a mismatch next to a 
single base bulge). However, if the mismatched nucleotide in the probe can 
complement the otherwise bulged base in the target, then the position of the bulge 
“shifts”, resulting in a single base bulge surrounded by matched pairs. In this case, 
both the wild type and mutant duplexes have a similar stability (both single base 
bulges).
- Such a situation cannot be avoided when the possible nucleotides for the 
mutation and the adjacent polymorphism are the same (e.g. both n.G>A).
* Alternatively, use a masking probe with an unmatched nucleotide or 
universal base at the polymorphism location.
Legend: Homozygous engineered templates of six different combinations of the c.1544G>A 
mutation and adjacent polymorphism sequences (c.1545G>A or C) were tested: GG, GA, GC, AG, 
AA, and AC. The three mutant allele traces are in red (AG, AA, and AC), while the three wild type 
allele traces are in blue (GG, GA, and GC). A: The wild type probe (WT HPA6 probe). B: Masking 
deletion probe. The mutant ‘AG’ allele with a Tm suggesting wild type is shown in bold type on the 
graph. C: The proposed duplexes of the two genotypes with very similar Tms are displayed. The 
target sequences are shown above the complementary masking deletion probe sequence, with the 
mutation location (MUT) and polymorphism location (POLY) indicated. The dash ‘ - ’ indicates the 
position of the probe deletion, located opposite the unpaired, bulged base. For the mutant ‘AG’ 
allele with the masking deletion probe, the expected duplex with a mismatch and a single base 
bulge at the POLY position is displayed above the predicted duplex with only a single base bulge 
at the MUT position. It is predicted that for both the wildtype ‘GA’ allele and mutant ‘AG’ allele, the 
single base bulge ‘A’ is surrounded by matched base pairs, resulting in similar Tms.







B. Masking deletion probe






GA target ccG ga 
Masking probe ggC - ct
Mutant 'AG' allele
Expected: Mismatch + Bulge
G
AG target ccA ga
Masking probe ggC - ct
MUT POLY Prediction: Bulge only
A
AG target cc Gga
Masking probe gg - c ct
MUT POLY
Conclusion
Clearly distinguished mutations from non-pathogenic polymorphisms.
- Reduce false positives, negatives.
Can mask polymorphism immediately adjacent to mutation.
- Locate mutations under probe (single nucleotide or codon).
- Distinguished mutant alleles of the same Tm with wild type probe
- Reduced the number of confirmatory, mutation-specific probes
Detect and genotype mutations without sequencing.
- Simplify probe melting analysis of complicated genes
Thank you: Dr. Highsmith (Mayo Clinic)
Reference: Closed-tube genotyping with unlabeled oligonucleotide probes and a saturating DNA dye 






Highsmith, William E., Ph.D.
From: Highsmith, W. Edward Jr., Ph.D. [Highsmith.W@mayo.edu]
Sent: Monday, March 22, 2004 3:42 PM
To: IRB Minimal Risk Protocol; Highsmith, W. Edward Jr., Ph.D.; Biospecimens
Committee
Cc: Highsmith, W. Edward Jr., Ph.D.
Subject: Request for Minimal Risk Protocol Approval
Minimal Risk Protocol Summary
This form will be submitted simultaneously to both the Institutional Review Board 
and the Biospecimens Subcommittee at Rochester or Scottsdale (if needed). In 
general, review and approval by both bodies is required prior to activation of the 
study.
Questions concerning the role of the Institutional Review Board should be 
directed to: Cindy L. Boyer, Research Services, 6-2808 
Questions concerning the role of the Rochester Biospecimens Subcommittee 
should be directed to: Cheryl Nelson, Rochester Research Services, 4-5920 
Questions concerning biospecimens in Scottsdale should be directed to: Linda 
Romme, Scottsdale Research Services, 2-4443.
Questions or comments regarding this form should be directed to the IRB Office.
LIVING OR DECEASED1 both 
BIOSPECIMENS1 YES 
DATATYPE1 deidentified 
EXTERNAL COLLABORATORS1 YES 
INTEND TO PUBLISH YES
PROPOSAL TITLE Provision of de-identified samples to ARUP laboratories for 
method validation 
SITE ROC















PROJECT PROPOSAL Melt-curve analysis is a newly developed technology
for the high-throughput, inexpensive detection of mutations in PCR amplified 
DNA. Dr. Rong Mao, a former fellow in the Mayo Molecular Genetics Laboratory 
(MGL), and colleagues at the University of Utah and ARUP Laboratories have 
developed a melt-curve analysis platform for the detection of mutations in the 
RET protooncogene using the hR1 High Resolution Melter from Idaho 
Technologies. Their work parallels work that is currently being done in the Mayo 
MGL using the same instrument. I propose to send Dr. Mao up to 60 de-identified 
samples that have been previously characterized with respect to RET gene 
mutations as part of clinical evaluations for the inherited cancer syndrome 
multiple endocrine neoplasia, type 2A. These samples either have been or will be 
evaluated on the HR1 platform in the Mayo MGL in an ongoing study exempted 
by the IRB April 1, 2003. We will collaborate on optimization and validation of an 
assay whcih could be faster and less expensive than currently existing methods. 
FUNDING SOURCE n/a 
FUND AMOUNT n/a
METHODS 1-2 examples of the approximately 40 disease causing RET 
mutations identifed by the Mayo MGL will be de-idetified and sent to Dr. Mao at 
ARUP Laboratories. No patient indentifiers will be included. The only information 
to accompany the specimen will be the identity of the RET mutation.
DATA OR SPECIMENS SOURCE Existing biospecimen 
OTHER DATA OR SPECIMENS SOURCE NotAnswered 
GCRC USEAGE No
COLLABORATOR NAMES Dr. Rong Mao
COLLABORATING INSTITUTIONS ARUP [ARUP is a commercial reference 
laboratory owned and operated by the University of Utah]
ACADEMIC INSTITUTION Yes 
COMMERCIAL INSTITUTION Yes 
BIOSPECIMENS OUTSIDE MAYO Yes
CONTACT INFORMATION Rong Mao, MD Associate Medical Director 
Molecular Genetics Section ARUP Laboratories Adjunct Assistant Professor of 
Pathology University of Utah School of Medicine Chipeta Way Salt Lake City, UT 
84108 Tel: 801-583-2787 x 3165 Fax: 801-584-5207 e-mail: 
rong.mao@aruplab.com
EXTERNAL COLLABORATOR ROLE Evaluation of the HR1 method for 
mutation identification in the RET gene.
CLINICAL MATERIAL TO EXTERNAL COLLABORATORS De-identified DNA
BIOSPECIMEN TYPE DNA
BIOSPECIMEN SOURCE DNA
BIOSPECIMEN OTHER SOURCE NotAnswered
BIOSPECIMENS COLLECTED Existing
BIOSPECIMEN SAMPLE NUMBER 60
BIOSPECIMEN IDENTIFICATION Other
OTHER ID Mutation previously identified in clinical test
SPECIMENS STORAGE BUILDING Hilton
SPECIMENS STORAGE FLOOR 9
SPECIMENS STORAGE ROOM 9-16
SPECIMENS STORAGE OTHER NotAnswered
BIOSPECIMEN GERMLINE TESTING YES
RESULTS TO PATIENT OR RECORD NO
DE IDENTIFIED DATA No
SURVEY RESEARCH NO
ROCHESTER EPIDEMIOLOGY USED NO
NON MAYO PATIENT INFO NO
RESIDENTS OLMSTED COUNTY NO
PARTICIPANT CONTACT NO
HIPAA WAIVER CONFIDENTIAL DATA Yes
HIPAA WAIVER SUBJECT IDENTIFIERS DESTROYED Yes
HIPAA WAIVER SUBJECT IDENTIFIERS Yes
HIPAA WAIVER IDENTIFICATION Yes
WAIVER CONSENT MINIMAL RISK Yes
WAIVER CONSENT NO ADVERSE EFFECT SUBJECT Yes
WAIVER CONSENT REQUIRED TO DO RESEARCH Yes








Please direct any questions regarding the completion 
of this form to the IRB Office at the phone extension 
or e-mail address to the left.
F r o m  : M a y o  F o u n d a t i o n  I n s t i t u t i o n a l  R e v ie w  B o a r d s  
201 B u i l d i n g ,  R o o m  4-60
P h o n e  4-2329 • F a x  8-0051 • e - m a i l  irb p ro g re ss re p o r ts@ m a y o .e d u
D a t e :  02/28/2005
T o : HIGHSMITH,W,E Jr., PhD
R e  : A n n u a l  R e v ie w  o f  IRB P r o t o c o l  701-04 R e v ie w  C o m m i t te e  :
"Provision of De-identified Samples to ARUP Laboratories for Method Valida
R e v ie w  T y p e : Expedited 
dited Review Committee
Progress Report Instructions and Report Form
P lea se  rea d  th ese  in stru c tio n s com pletely  a n d  care fu lly
According to our records, the IRB has previously sent a progress report reminder notification. Federal regulation [45CFR46.1009(e)] 
requires the Institutional Review Boards (IRB) to review protocols at intervals appropriate to the degree of risk, but not less than once 
per year. At this time, the due date for the above named protocol’s annual review is now 30 days away. A pproval o f  th is protocol 
w ill exp ire on Mar-29-2005 unless the IR B  approves a com pleted  progress report prior to th is date. You are responsible 
for submitting a continuing or final progress report with all required materials in time for review by the IRB before this expiration date. 
Failure to submit a complete progress report may cause your protocol to expire before it can be approved. Please note that the deadline 
to make an Expedited Review Committee agenda, the deadline is noon central time, the Thursday prior to the meeting. Note that the 
deadline for an agenda may change due to holidays.
A complete progress report m ust include a single-sided copy of the most recently IRB-approved consent form(s) (if applicable). 
Double-sided copies will not be accepted. This document does not need to be included if the answer to 3a is “Yes” and the number 
entered for question 4 is “0” (zero).
DO NOT include registration numbers (clinic numbers) or any other patient identifiers in your progress report submission.
If all supporting documents to the progress report can be sent electronically, please e-mail the documents (along with this completed 
form) as separate attachments in the same e-mail, using "Progress Report" for the subject, to irbp rog ressrepo rts@ m ayo .edu . Do not 
combine the progress report form with other materials into a singular attachment for e-mail. Submissions of this kind will not be 
accepted by the IRB.
If any of the supporting documents cannot be sent electronically, please print this completed progress report form, place it on top of the 
packet of the supporting documents, and send the entire packet to: IRB Progress Reports Secretary, 201 Building, Room 460.
P lea se  do n o t su b m it m o re  th a n  o n e  copy o f  y o u r  co m p le ted  p ro g ress  report to  th e  IR B .
K eep  a copy o f  y o u r  en tire  p ro g ress  report f o r  y o u r  records!
If the protocol involves the General Clinical Research Center (GCRC), you are responsible for sending a complete copy of the progress 
report and all supporting materials (except the protocol) to Shari Brumm, GCRC, Domitilla 5-521
Mayo Foundation Institutional Review Boards Progress Report Form -  Minimal Version VI • Updated 12/09/2004
MAYO FOUNDATION




Name of Principal Investigator: HIGHSMITH,W,E Jr., PhD
Review Type: Expedited
IRB #: 701-04 Review Committee: Expedited Review Committee
Title: "Provision of De-identified Samples to ARUP Laboratories for Method Validation"
Expires: Mar-29-2005
If the IRB consent type for this protocol is “waived,” please complete the online progress report form at 
http://wolfpack2.mayo.edu/resis/irb/chart_review.cfm instead of using this form. The address above will need to be typed into
your web browser's address bar.
Please complete this form by clicking on the appropriate check boxes and typing in the text fields.
PLEASE TYPE ALL NARRATIVE COMMENTS
Conflicts of Interest: The following reflects the current status for all study personnel:
There are no new conflicts to disclose
I I One or more study personnel now have a conflict of interest. (Please contact the Conflict of Interest (COI) Review Board to 
report and resolve this conflict before submitting to the IRB. A copy of the minute item response from the COI Review Board 
should be forwarded with this submission).
Please answer the following question BEFORE continuing with the rest of this form.
Does this IRB number refer to a grant application under which all active protocols are separately submitted
to the IRB for review (i.e., no subjects are enrolled or no patient data collected under this IRB num ber)?.................Yes □  No |EI
^  If “Yes”, please list the IRB numbers (or titles if an IRB number has not yet been assigned) of protocols supported by this 
grant in the box below and then answer only questions 1 and 2.
COMPLETION OF THIS SECTION IS REQUIRED FOR ALL STUDIES WHERE HIPAA AUTHORIZATION IS NOT BEING OBTAINED
Request for Waiver of HIPAA Authorization
A Request fo r  Waiver o f  HIPAA Authorization is required in accordance with 45 CFR 164.512(i).
Please complete this section by checking all boxes that apply.
All study data will be treated in a confidential manner and the same precautions used to protect patient clinical data will be 
employed.
NOTE: I f  you are unable to check this box, please describe in the box below the precautions that will be taken to pre-vent inappropriate use o f  the data.
All subject identifiers will be destroyed upon completion of the research.
NOTE: I f  you are unable to check this box, please explain in the box below why the retention o f  the identifiers is appropriate.
1X1 I certify that the subject identifiers will not be reused or disclosed to any other person or entity, except as required by law, for 
authorized conduct and oversight of the study, or for other IRB-approved research.
^  The research could not be practicably carried out without access to and use of the subjects' identifying information.
I. Protocol Status
1. Do you want to continue this protocol in an active status? (If any participants are still receiving 
study intervention or are being followed per protocol, the protocol must continue in an active 
status.) ....................................................................................................................................................................... .Yes □  No |EI
Mayo Foundation Institutional Review Boards Progress Report Form -  Minimal Version VI • Updated 12/09/2004
2. This protocol is being conducted under this IRB number at (check aU that apply)......... MCR □  MCJ □  MCS □
If this protocol is being conducted at more than one Mayo site under this IRB number, it is the responsibility of the protocol's principal investigator to 
submit a progress report that includes data from all participating Mayo sites.
II._____ Protocol Activity
3a. Is the research permanently closed to the enrollment of new people?..................................................................... Yes ^  No EH
3b. If “Yes”, have all currently enrolled participants completed study interventions? ..............................................Yes No □
4. How many participants have been enrolled at Mayo since IRB approval was last received?.....................................50
If this is the first progress report for this protocol, please enter the same number in questions 4 and 5. Do not leave either field blank.
5. How many participants have been enrolled at Mayo since the study was originally approved?................................ 50
6. How many participants (at Mayo) have been approved for enrollment by the IRB?.....................................................60
7. If the IRB approved screening of additional participants in order to meet target accrual, please indicate 
the total number approved for screening (that is, the total number approved for enrollment plus
additional screens)......................................................................................................................................................................60
If there is no approval of additional participants for the purposes of screening, please enter the response from question 6 in the box for question 7. Do not 
leave either field blank.
8. Are Mayo participants still being followed per protocol?...........................................................................................Yes □  No |EI
9. Briefly summarize (in the box below, in 200 words or less) the protocol activity since IRB approval was last received. 
Include progress to date and future plans.
50 de-identified samples with previously characterized RET protooncogene mutations were sent to Dr. Mao at 
ARUP Laboratories for validation of a new test protocol. Results have been presented as a poster at a 
national meeting.
10a. Have any changes occurred to the Mayo personnel involved with this study that have not been
submitted to the IRB via the Protocol Modification Request Form?................................................................ Yes EH No
10b. If “Yes”, please list in the box below the full name and role (i.e., principal investigator, co-investigator, study coordinator, 
etc.) of all Mayo personnel being added or removed from the study. If any personnel are being replaced, please indicate if 
they will be remaining on the study under a different role.
Remember that personnel must successfully complete the Mayo Training Program for Protecting Human Subjects (http://researchweb.mayo.edu/mtp-phs/)
prior to participating in a human research project.
11a. Have any changes in the specific aims, study procedures, or consent form occurred that have not been
approved by the IR B ?....................................................................................................................................................... Yes EH No
11b. If “Yes”, please explain in the box below.
12a. Have any changes in the eligibility criteria occurred that have not been approved by the IRB?.........................Yes □  No |EI
12b. If “Yes”, please explain in the box below.
13. Since IRB approval was last received, has the study been audited or monitored by any outside sources
(i.e., study sponsor, ECOG, NCCTG, NCI, e tc .)? .......................................................................................................Yes EH No
If “Yes”, a copy of the sources' audit report, monitor report or summary must be included with this progress report.
14a. Has anything appeared in the pertinent medical literature that affects the conduct of this study, the
anticipated benefits, or the potential risks?................................................................................................................... Yes □  No |EI
14b. If “Yes”, please explain in the box below.
15. If any publications or presentations have resulted from the work related to this study, please list them in the box below. 
Abstract - 1.Margarf RL, Mao R, Highsmith WE, Holtegaard LM, Wittwer CT, Mutation scanning of the RET 
protooncogene using unlabeled probes and high-resolution melting analysis. J Molec 
Diag 2004; 6(4):435.
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III. Review of Risks to Research Participants
16a. Have any additional risks been identified since IRB approval was last received?................................................Yes □  No |EI
16b. If “Yes”, and these risks have not been reported to the IRB, please summarize in the box below.
17a. Briefly describe (in the box below) the frequency and severity of all adverse events (including those already reported to the IRB) 
that have occurred since IRB approval was last received.
None
The investigator is reminded that all serious adverse events must be reported to the Serious Adverse Events/Deviations Board. Do not attach SAE/Deviation 
forms to this progress report.
17b. Also indicate (in the box below) whether the adverse events are similar in type, frequency and severity to what was expected 
before the study, and if not, how they differ from expectations.
17c. If this protocol is a multi-center study, please also describe (in the box below) whether M ayo’s experience with adverse events in 
this study is comparable with that at other institutions.
18a. Was there any unusual increase in the frequency of serious but expected adverse events among Mayo
participants?........................................................................................................................................................................Yes □  No □
18b. If “Yes”, please describe in the box below.
IV. Informed Consent Evaluation -  (Applies to both written and verbal consent)
19a. Have any problems occurred with regard to obtaining and documenting of the informed consent?..................Yes □  No □
19b. If “Yes”, please describe in the box below.
20. In the box below, briefly state each reason for the withdrawal of research participants (whether voluntary or not) from the study. 
For each reason given, please state the number of research participants withdrawn since IRB approval was last received.
21a. Have there been any unanticipated problems with the retention of participants?.................................................. Yes □  No □
21b. If “Yes”, please describe in the box below.
22. Are the consent/assent form documents still acceptable (i.e., the information contained in the 
document is accurate and complete and there is no new information that may have been
obtained since the last IRB approval which should be disclosed to participants)?.... Yes □  No □  Verbal Consent □  
If “No”, please e-mail (to irbprogressreports@mayo.edu) an electronic copy of all recommended changes to the consent/assent form(s).
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Research: Pre-Submission Approval Form
Approval is required before information is presented outside of ARUP and enters the public 
domain to ensure that HIPAA and IRB protocols have been followed. Please ensure that this 
document is signed and appropriate documents are attached before submitting any information 
for publication/presentation outside of ARUP.
f/1 Attach copy of (please indicate) manuscript, poster, abstract, or other presentation
Presentation/Poster presented at (specify meeting or conference): _____ formoiecuiar pathoiogyme_ing 
ARUP Cited: Yes \7} No O  If no, state reason: ________________________________
AR|P LABORATORIES
Salt Lake City. Utah
□  Global IRB #7275 applies, and PRCS-0020, Internal Sample Request: De-Identification o f  
Samples has been followed OR
Independent Institutional Review Board (IRB) approval, IRB# 000-00_______________
Attach copy of approved IRB protocol.
OR
I I IRB is not applicable. Please explain:____________________________________________
Scientist/Researcher:______________________________________  Date:.
Signature
Approval Signatures and Dates:
Medical Director: Date:
R&D Group Manager or
ARUP Privacy Officer:____________________________________  Date;
CONFIDENTIAL: This material is prepared pursuant to Utah Code Annotated, 26-25-1, et seq., for the purpose of 
evaluating health care rendered by hospitals or physicians and it NOT PART of the medical record.
